To include your compound in the COVID-19 Resource Center, submit it here.

Studies differ on cost-effectiveness of PCSK9 inhibitors

Two updated cost-effectiveness analyses published in the Journal of the American Medical Association and JAMA Cardiology based on data from the Phase III FOURIER cardiovascular outcomes trial (CVOT) suggest that the price of PCSK9 inhibitors, including Repatha evolocumab from Amgen Inc. (NASDAQ:AMGN), would need to be reduced to meet cost-effective thresholds.

Data from FOURIER released in March showed that Repatha significantly reduced the risk of myocardial infarction (MI) and stroke, but failed

Read the full 713 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE